Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence
The aim of this study was to determine predictors of the response to escitalopram , a selective serotonin re-uptake inhibitor antidepressant and memantine , a non-competitive glutamate NMDA receptor blocker , for the treatment of major depression comorbid with alcohol dependence . Eighty alcohol dependent treatment-seeking adult patients with comorbid major depressive disorder were r and omized to receive either memantine 20 mg or escitalopram 20 mg for 26 weeks . In both treatment groups , depression was reduced significantly . Comparisons were made between patients in remission ( final Montgomery-Asberg Depression Rating Scale (MADRS)<or=12 ) and non-responding patients ( MADRS decrease<50 % ) . The age at onset of the first major depressive episode significantly correlated with the treatment response in the escitalopram group ; the mean age at onset of depression among patients on the non-responders group was 13.7+/-4.0 years and 31.9+/-11.9 years in remission . These results are significantly different from those with memantine . Our study provides evidence that the onset of the first major depressive episode might be a clinical ly relevant predictor of a response to escitalopram treatment in patients with major depression and comorbid alcohol dependence
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .